Cardiovascular disease (CVD) continues to be the leading cause of death globally, highlighting the need for innovative therapeutic solutions. Bristol Myers Squibb, with its history of success in treating CVD and dedication to bold scientific advancements, is actively working towards transforming CVD treatment.
By employing a precision medicine approach to CVD research, Bristol Myers Squibb’s scientists utilize genetics and a deep understanding of human biology to identify disease subsets and targets, develop new medicines, and apply the appropriate modality. This approach has led to groundbreaking discoveries and the development of new therapies aimed at addressing the unmet needs of patients with CVD.
Over the past century, significant progress has been made in reducing the death rate from CVD through scientific breakthroughs in nutrition, exercise, coronary blood flow interventions, and the development of drugs to manage blood pressure, cholesterol levels, and other risk factors. Despite these advancements, challenges in CVD treatment persist, underscoring the importance of continued research and innovation.
Bristol Myers Squibb has been at the forefront of advancing CVD therapies, with the development of ACE inhibitors, cholesterol-lowering agents, anticoagulants, and other treatments that have revolutionized heart health care. Leveraging their expertise and strategic research approach, the company is focused on developing new therapies for diseases with high unmet needs.
The precision research approach adopted by Bristol Myers Squibb is rooted in causal human biology, enabling researchers to identify new therapeutic options for CVD. By targeting mechanisms that act directly on the heart muscle, such as cardiac myosin inhibition, the company is redefining the treatment landscape for conditions like hypertrophic cardiomyopathy and heart failure with preserved ejection fraction.
In addition to their work in cardiac myosin inhibition, Bristol Myers Squibb is accelerating the development of new medicines for thrombosis based on a strong understanding of causal human biology. Through collaborations like the one with Johnson & Johnson, the company is exploring FXIa inhibition for the prevention and treatment of major thrombotic conditions.
Bristol Myers Squibb is committed to improving the lives of patients with CVD by developing next-generation therapies that not only enhance clinical outcomes but also improve quality of life. By focusing on patient-centric clinical trial endpoints and collecting real-world data, the company ensures that their medicines are safe, effective, and offer long-term benefits to patients with CVD.
With a scientific discovery engine rooted in causal human biology and a precision medicine approach to research, Bristol Myers Squibb continues to lead the way in pioneering life-changing cardiovascular therapies. Their dedication to advancing the field of CVD treatment and commitment to improving patient outcomes underscore their role as a key player in the fight against cardiovascular disease.
